Meetings and materials

The P&T Committee / DUR Board meet at least quarterly. All meetings are open to the public.

Seeking applications for P&T Committee members

The Washington State Health Care Authority is seeking applications from interested physicians, pharmacists, and physician assistants to fill four openings on the Washington State Pharmacy & Therapeutics (P&T) Committee beginning on February 1, 2025. The initial term of appointment is 3 years. Members of the committee are expected to attend six full day virtual meetings a year, with a few hours of reading to prepare for the meeting. Members of the committee will be compensated for attendance at meetings in accordance with a personal services contract executed after appointment to the committee. View the solicitation letter for more information.

Meetings and materials: Pharmacy and Therapeutic (P&T) Committee/Drug Utilization Review (DUR) Board

2024 meeting schedule

February 28
April 17
June 26
August 14
October 16
December 11

Materials

Drug class reports will be taken down 30 days after the meeting.

Date	General documents	P&T Documents	DUR documents
October 16, 2024 9 a.m. - 4 p.m. WEBINAR ONLY	Topic agenda (10/16/2024) October webinar recording (10/16/2024)		Drug class review – Magellan DUR Bone Density Regulators Parathyroid Hormone Derivatives policy DUR Bone Density Regulators Rank Ligand Inhibitors policy DUR Bone Density Regulators Sclerostin Inhibitors policy DUR Drug Class Motions DUR Policy Motions
August, 14 2024 9 a.m. - 4 p.m. WEBINAR ONLY	Topic agenda (8/14/2024) August webinar recording (8/14/2024) P&T/DUR transcript (8/14/2024)		Drug class review – Magellan DUR drug class slide Cytokine and CAM Antagonists IL-1 Inhibitors policy Cytokine and CAM antagonists-IL-4/IL-13 inhibitors policy Cytokine and CAM antagonists-IL-6 inhibitors policy Cytokine and CAM antagonists-IL-12/IL23 inhibitors policy Cytokine and CAM antagonists-IL-17 inhibitors policy Cytokine and CAM Antagonists Integrin Receptor Antagonists policy Cytokine and CAM Antagonists Janus Associated Kinase (JAK) Inhibitors policy Cytokine and CAM antagonists-oral PDE-4 inhibitors policy Cytokine and CAM Antagonists S1-P Receptor Modulators policy Cytokine and CAM Antagonists T-Lymphocyte Inhibitors policy Cytokine and CAM antagonists-tumor necrosis factor inhibitors policy Annual antidiabetics utilization review DUR Drug Class Motions DUR Policy Motion
June 26, 2024 9 a.m. - 4 p.m.	Topic agenda (6/26/2024) June webinar recording (6/26/2024) P&T/DUR transcript (6/26/2024)	Antiemetic motion Asthma controller COPD motion Asthma quick relief motion Long-acting opioids motion Overactive bladder motion Archived drug class motion	Drug class review - Magellan DUR utilization DUR drug class motions
April 17, 2024 9 a.m. - 4 p.m.	Topic agenda (4/17/2024) April webinar recording (4/17/2024) P&T/DUR transcript (4/17/2024)	MS drugs motion Second Generation Antipsychotics Motion TIMs motion	Drug Class Review - Magellan Antihemophilic Hemgenix Policy Immune Modulators Thalidomide Analogs Policy Movement Disorder Agents Policy DUR Drug Class motion DUR Policy Motion
February 28, 2024 9 a.m. - 4 p.m. WEBINAR ONLY	Topic agenda (2/28/2024) P&T committee / DUR Board process overview February webinar recording P&T / DUR transcript (2/28/2024)	Statins motion Antiplatelet motion Anticoagulant Motion PCSK9 Inhibitors Motion Archived Drug Class Motion ADHD Motion	Apple Health drug class review - Magellan Asthma and COPD agents: Omalizumab (Xolair) draft policy Endocrine and Metabolic Agents: Teprotumumab (Tepezza) draft policy Oncology Agents: Androgen Biosynthesis Inhibitors draft policy DUR Policy Motion DUR Drug Class Motion

Meeting details

All P&T Committee/DUR Board meetings are open to the public.
Stakeholders will be allowed three minutes for comments.
Written testimony: If you would like to give testimony, but cannot attend a meeting, please email a two-page maximum letter to the WPDP program at least one week before the meeting. If you provide new drug information that has not been reviewed by the Drug Effectiveness Review Project (DERP), it cannot be considered by the committee.
Committee discussion and motions follow stakeholder comments.
For Apple Health PDL or drug policy questions email Apple Health Pharmacy Policy.
Meetings are sponsored by the Health Care Authority and meet requirements of the Americans with Disabilities Act. Please call our ADA Coordinator at 360-725-9976 to make a request for special accommodations. TRS users may call this number through the Washington Relay Service by dialing 711.

Meetings held by webinar

If you would like to speak on any topic listed on the agenda, email the WPDP program, by the Friday before the meeting date:

Your name;
The organization you represent; and
The drug class name on the agenda.

The Committee Chair will call these names after the drug class presentation. You will be unmuted and have 3 minutes to speak. If you do not sign up ahead of time, but would like to speak at the meeting, the Committee Chair will ask if there are any other stakeholders. "Raise your hand", you will be unmuted when your name is called. You will have 3 minutes to speak. You can also ask questions in the "chat" box.

Meetings held at the Conference Center

Directions to The Conference Center in Sea-Tac airport.
Sign up at the meeting to testify on a drug class. Stakeholder sign-up sheets are located in the lobby.

Medicaid supplemental rebates

Effective January 1, 2018 HCA joined The Optimal PDL Solution (TOP$) supplemental rebate pool administered by Provider Synergies, a subsidiary of Magellan Medicaid Administration, LLC.

Please refer to the TOP$ website for more information about contracting and submitting rebates.

Request archived materials

To request archived materials, email the Prescription Drug Program.

Stakeholder list

If you would like to receive P&T/DUR meeting agendas and drug class updates sign up for the Prescription Drug Program Stakeholder List.